

**OTC Markets**

Joining us today is Jim Gilligan the CEO and chief scientific officer of Tryp Therapeutics the trace on our OTCQB Venture Market under the ticker TRYPF Tryp Therapeutics is a pharmaceutical company. Focused on developing psilocybin-based components for the treatment of diseases with unmet medical needs through accelerated regulatory pathways Jim thanks so much for joining us today.

**Jim Gilligan**

Well thank you for having me I'm pretty excited about being able to share. All the exciting things are going on with Tryp Therapeutics.

**OTC Markets**

Absolutely thanks for joining us here in New York so to start tell us about your leadership experience in the biotech and life sciences space and how you got involved with Tryp.

**Jim Gilligan**

Yeah, that's great questions so I've been in biotech and drug development for about 35 years started out in biotech and was involved in all aspects of drug development from preclinical through clinical regulatory and came very knowledgeable what it takes in order to get drugs approved and I mentor some younger folks I say you know you could have a drug that cures cancer but if you don't get it through the regulatory hurdles approved. You won't help patients and won't help your investors and so I think understanding what it takes is important and one of the things that Um, is interesting about the psychedelic space is that we have molecules. We know that they have biology, right? and we know they have safety we understand how they work and it's very similar to what I've done in my time where I've worked primarily with drugs that already have been approved. Like people were talking about Ozempic for diabetes now It's for weight loss and so you can do things where you go for new indication, and you know you have a pretty high likelihood of success similarly I worked fair amount on changing the root of administration so say have a drug that has to be injected like insulin what if you could come up with an oral tablet that's more patient. Friendly again you know insulin works. You know it's safe now you just need to develop the you know the new technology and show that it works. And that's similar to what we have here because again we understand the molecules and so I think we do have opportunity to de-risk and have a higher likely of success and it does build upon my experience in that sector. It's called from. FDA perspectives called the five Zero five b two so that's the approach that you take yeah

**OTC Markets**

So, let's talk about trip. Ah, talk about your drug development programs and the types of disorders that you specifically target.

**Jim Gilligan**

So, what we did purposely is we decided to look at what unmet medical needs are not being addressed by some of the competition. So, you know if you look at most of the companies that are in treatment-resistant depression anxiety people start looking at PTSD we decided to go down a path a little less well-trodden and so we looked at initially binge eating disorders. Ah, talk a little bit about that then chronic pain the medical term for is neuropathic pain. It's pain that originates in the brain and the perfect example of that is actually phantom limb or unfortunately a service man or you're in a car accident. You lose an extremity and then later on you have pain. In that extremity that no longer exists so clearly that signal comes from the brain and more recently in a collaboration with Harvard MGH we're looking at abdominal pain and visceral tenderness in patients with IBS. So really distinct areas where there's not a lot of drugs available. And areas where we think that there'll be potential for psychedelic assisted psychotherapy.

**OTC Markets**

Tell the best tell about you know, talk about your some of your scientific collaborations and clinical activities.

**Jim Gilligan**

So what? what. Our mantra is that there's people out there who are experts in their respective field. They're subject matter experts. So, at university of Michigan, we have Dr Dan Claw who's been involved in fibromyalgia and chronic pain research for over 20 years. We have Rob Carhart-Harris chairs or scientific advisory board probably the preeminent psychedelic research in the world and so what we do is we try to team with experts in their respective area. Dr. Jennifer Miller down in Florida and so by doing that we leverage their expertise. They're the real experts in their respective indication and we bring in the psychedelic expertise the regulatory expertise in DEA and we combine that in order to move forward clinical programs.

**OTC Markets**

How has the regulatory landscape and public opinion changed in recent years on the acceptance of psychedelics as medical treatments.

**Jim Gilligan**

It's been quite remarkable if you look at the wall street journal you look at time magazine you look at the fact that FDA has given accelerated ah status for some of the different psychedelics the number of leading academic institutions Cecilia have you know NYU here you have Johns Hopkins and you have really prestigious institutions looking at primarily psychedelic assisted psychotherapy in almost all cases. It's an integrated approach. The drug is part of a treatment with therapist. And that and it's I think the stigma has really been pretty much removed and people can start seeing the benefit plus all the data that's coming out where people are reporting really good clinical outcomes is I think you're starting to recognize the potential for these psychedelic treatments.

**OTC Markets**

What milestones and partnerships do you anticipate for trip and 2023 and beyond.

**Jim Gilligan**

Okay, so yeah, let me go into 2024 a little bit. So, what we one of the things we did is so we went down something different. We did the binge eating and we reported. Ah, first quarter this year that the results were actually even better than we may have anticipated 80% reduction in binge eating episodes 84% improvement how often the patients felt that they lost control over their eating behavior and. Tremendous for the patients to decrease in anxiety scores and depression. So that shows that that approach was well warranted validated and so stay tuned hopefully that next but by the end of May we should have another I and d submission. Announced for our study at Mass General Hospital and just ah this week in touch with our folks, our friends, our colleagues at university of Michigan to arrange for them to receive the clinical trauma material so we can get that study kicked off, so we have those 2 and then in parallel. We're working on Tryp 8803 which is our proprietary ivy infused silasin which we think is going to be really important because this addresses a number of the limitations associated with orally administered psilocybin.

**OTC Markets**

Tryp Therapeutics on the OTCQB venture market and is also traded on the CSC how it's cross trading on the OTCQB market enhancing your investor strategy here in the Us?

**Jim Gilligan**

---

So, we feel that the U is pivotal for our success and having OTCB opportunity. Is really important and we want to be able to reach out to US investors. We want them to understand what we think is unique and exciting and um, we you know I kid people sometimes you say that you know. You don't want to be the best kept secret in the industry. You know you want people to really get understand and get excited about what we're doing, and we think this affords us a tremendous opportunity to achieve that

**OTC Markets**

well Jim it's been a pleasure to speak with you and thank you so much for coming to visit us with here in New York

**Jim Gilligan**

I have to thank you for giving us the opportunity and very excited about being able to share the trip story

**OTC Markets**

Tryp Therapeutics traits another the symbol TRYPF on our OTCQB Venture Market.

*\*This is an autogenerated transcript and may contain typos.*